Intervet/Schering-Plough Animal Health, has launched a new guide entitled ‘Your guide to Exotic Diseases', to educate horse owners on these potentially fatal, insect-borne diseases, some of which are zoonotic.
Joining the company's guides on respiratory disease and vaccination, the leaflet features information on West Nile Virus, African Horse Sickness, Equine Infectious Anaemia (Swamp Fever) and Equine Encephalitis including overviews of each of the diseases and their clinical signs.
Spread by a variety of insect-borne vectors including midges, mosquitoes and horseflies, climate change is increasing the risk of exotic diseases having a severe impact on the country's equine industry. What's more, African Horse Sickness is transmitted from animal to animal by infected biting Culicoides midges, the same midges that carry the Bluetongue virus which has threatened UK livestock this year.
"It's essential that horse owners are aware of the threat of exotic diseases coming in from overseas and the clinical signs to look out for, especially during the summer and autumn months when diseases transmitted by insects are more likely to appear." comments Tim Zoch, Marketing Manager at Intervet/Schering-Plough Animal Health. "Our new leaflet features easy-to-understand overviews of each of the diseases to help educate owners, and practices can expect strong demand from their clients"
For further information about Intervet/Schering-Plough's range of horse owner guides, including ‘Your guide to Exotic Diseases', please contact your Intervet/Schering-Plough Account Manager or call the Veterinary Support Group on 01908 685685.
Merial Animal Health has announced that it has purchased the the anti-inflammatory treatment for lameness in horses, Hyonate® (sodium hyaluronate), from Bayer.
Merial's equine marketing and technical manager, Louise Radford MRCVS said: "Hyonate is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection.
"The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism¹."
For more information telephone Customer Support on 0870 6000123 or contact your local Merial Equine Specialist.
Reference
Omics refers to a field of biological sciences including genomics (studying DNA), transcriptomics (RNA), proteomics (proteins) and metabolomics (metabolites).
Guest Editor Carrie Finno has contributed an editorial in support of the nine EVJ articles demonstrating how genomic and transcriptomic approaches have been used to investigate equine diseases.
She said: “While equine genomics and transcriptomics continue to evolve, improvements in the annotation of the equine genome will undoubtedly accelerate the rate of discovery.
"With the need for large sample sizes of well-phenotyped horses to study the most complex diseases, equine genomics and transcriptomics research will likely become increasingly collaborative, similar to the current status of human genomics initiatives.
"Aligned with this collaborative effort is the strong need for publicly available genomic and transcriptomic data that are accessible to all researchers.”
Guest Editor James Anderson prefaces five papers on advances made in equine medicine within the disciplines of proteomics, metabolomics and lipidomics (a subset of metabolomics).
He said: “Omics technologies have enhanced our knowledge of the molecular world and provided fascinating insight into the composition and functions of these components across a range of different animal species.
"Particularly for equine science and medicine they have increased our understanding of molecular changes in disease and informed the development of diagnostic tests.
"Although still in its infancy within equine veterinary science, this field looks likely to have a significant impact in the coming years.”
The virtual Issue is available to all at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.OmicsEVJ
This year's National Equine Health Survey, conducted by the Blue Cross and supported by Zoetis, has revealed that 20% of owners who claimed to have treated for encysted small redworm (ESRW) used a wormer that was not indicated to treat the parasite.
3,669 horse owners took part in the survey, which was conducted in May 2014. It contained 25 questions on general horse health, care and management and was validated by Professor Josh Slater at the Royal Veterinary College.
Zoetis says the findings suggest that horses are being left at serious risk (untreated, encysted small redworm may develop and emerge en masse from the gut wall, causing diarrhoea and colic with a mortality rate of up to 50%1).
The company is now running an encysted small redworm awareness campaign at www.esrw.co.uk, where owners can test their knowledge before discussing the best treatment options with their vet.
References
1. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242
Pfizer Animal Health is reminding horse owners of the importance of treating encysted small redworm larvae this autumn.
According to the company, these hidden, dormant parasites can account for up to 90% of the redworm burden in a horse (1). Furthermore, encysted small redworm larvae won't show up in a faecal egg count (FEC). Even if a horse has shown a negative or low count it could still be harbouring several million harmful larvae, hidden within the gut wall (2)
Encysted small redworm are a potential time bomb, with the ability to survive inside a horse for up to two years. They usually 'wake-up' in the late winter or early spring, developing and emerging from the gut wall all at the same time. Such a sudden mass emergence can cause a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate (2). Treating encysted small redworm successfully in the late autumn or early winter is vitally important in order to prevent this serious risk.
Pfizer says that Moxidectin, the key ingredient of EQUEST, is recognised as the only single dose treatment for encysted small redworm. It has been shown to kill the larvae in-situ, without resulting in severe inflammation of the gut wall that other multi-dose treatments may cause (3). In addition, Moxidectin is licensed for persistent activity against small redworm over two weeks, killing larvae ingested as the horse grazes for up to two weeks after treatment.
Ben Gaskell, Pfizer's veterinary advisor said: "A responsible and sustainable worming programme involves good pasture management, regular diagnostic tests and targeted worming, carefully planned using specialist advice. However, it is also vital to remember the danger of encysted small redworm. Even if a horse's FEC is clear, there could still be a significant encysted small redworm burden that must be treated properly every year in late autumn / early winter."
1) Bairden K. et al (2001) Veterinary Record 148, 138-141 2) Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242 3) Steinbach T. et al (2006) Veterinary Parasitology 139, 115‑131
Chanelle's head of sales and marketing, Killian Gaffney said: "The total UK market is around 80,000 bottles annually. However, with the major supplier announcing some re-stocking in March but full availability still under question, there is a real sense of urgency for practitioners.
"The Chanelle team worked throughout December with our manufacturing division to ensure that the UK product shortfall could be alleviated.
"Air freighting supplies seemed the obvious course of action, and ensured we could supply the UK market as quickly as possible."
For further information, contact: Chanelle on 00353 91 841 788.
Research published in EVE by Pearson in 2020 reported that 95% of equine vets work with “difficult” horses on at least a monthly basis, and that 81% of them had sustained at least one injury in the last 5 years.
The research also indicated that some vets overestimate their understanding of equine learning theory.
The BEVA says developing an extended understanding of how horses learn can make clinical care less stressful, and that reduced patient stress also improves workplace safety, which is important in a role that has been identified as one of the most dangerous civilian professions.
Gemma said: “Horses have limited cognitive skills and so we should try to better understand what motivates and reinforces unwanted behaviours rather than assuming the horse is being wilfully or maliciously disobedient.
“To do this we need to appreciate how horses learn.
"Better horse handling leads to happier horses, and this means happier vets and nurses and owners/clients with the ultimate knock on of better safety, better job satisfaction and better retention in the profession.”
The training sessions include:
Gemma added: “One of the biggest push backs I get from people that haven’t started to develop low stress vet care as a routine is that they haven’t got time. But those who do use it say that it saves them time and keeps them safer, this also brings obvious commercial benefit to the practice - so what’s not to like?”
https://www.beva.org.uk/elearning-redirect?redirect=/course/view.php?id=622
Equine glandular gastric disease is a complex syndrome that is distinct from gastric ulceration. A number of studies now indicate that it is an inflammatory gastritis, predominantly at the gastric outflow, which has different causes and risk factors from gastric ulcers. As such, medication effective in treating gastric ulceration may be less effective for this specific condition.
The clinical signs of EGGD are diverse and non-specific and may be mild or recurrent. They may include changes in temperament, changes in rideability, unexplained weight loss, reduced appetite or cutaneous sensitivity manifesting as biting of the flanks or resentment of girthing, grooming, leg aids or rugging. Recommendations for reducing the prevalence of disease, based on putative risk factors, include providing rest days from work, maximising turn-out, minimising management changes and other potential stress factors and minimising changes in equine companions and human carers.
The new guidelines have been published by a group of equine medicine specialists, based on a review of published and unpublished evidence. The intention is to provide veterinary practitioners with up-to-date guidance on risk factors, diagnosis, treatment, dietary management and prevention of EGGD.
David Rendle, an internal medicine specialist at Rainbow Equine Hospital in North Yorkshire who chaired the group and is a consultant editor of UK Vet: Equine said: "Our findings challenge long-standing dogma on EGGD, a condition about which there is currently very little advice available to vets and horse owners. It is becoming increasingly clear that the distinction between disease of the squamous and glandular mucosa is important clinically and the group felt that updated guidance may help to improve management of EGGD in practice."
Provision of evidence based clinical guidelines should enable practitioners to adopt more standardised and logical approaches and base EGGD management decisions on the most current data.
Professor Josh Slater, Professor of Equine Clinical Studies at the Royal Veterinary College said: "Clinical guidelines are commonly used in human health care and have been shown to improve clinical outcomes by condensing data from large numbers of research publications and promoting rapid adoption into clinical practice. These new guidelines represent a step forward in the management of this complex condition by combining a consensus of expert opinion with the best available current clinical research and evidence."
Mark Bowen, Professor of veterinary internal medicine at the University of Nottingham who is based at Oakham Veterinary Hospital said: "Whilst the panel hasn’t come up with miracle cures there was universal agreement that new treatment options have to be integrated in a logical and responsible manner."
"Our understanding of this condition is in its infancy but we hope that the summary document, which also highlights the gaps in our knowledge, will provide a useful framework for vets to follow and will be a stimulus for future research."
The guidelines can be found here: https://www.magonlinelibrary.com/doi/full/10.12968/ukve.2018.2.S1.3
Photo: Marked multi-focal depressed haemorrhagic and fibrinosuppurative lesions
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
According to the AHT, there is undisputed evidence that owners, riders and trainers have a poor ability to recognise signs of pain seen when horses are ridden. As a result, problems are labelled as training-related, rider-related, behavioural, or deemed 'normal' for that horse because 'that’s how he’s always gone'.
This, says the AHT, means pain-related problems are often disregarded, the horse continues in work, and the problem gets progressively worse.
Dr Sue Dyson, Head of Clinical Orthopaedics at the AHT, believes it may be easier to educate riders and trainers to recognise changes in facial expression and behaviour rather than lameness. So she and her team set out to develop and test an ethogram to describe facial expressions in ridden horses and to determine whether individuals could interpret and correctly apply the ethogram consistently.
At this stage in the project, they concluded that their ethogram could reliably be used to describe facial expressions of ridden horses by people from different professional backgrounds (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(16)30184-8/fulltext).
In the next stage of the project, Sue and her team sought to demonstrate that the ethogram could be used to identify lameness.
The ethogram was applied blindly by a trained analyst to photographs (n=519) of the head and neck of lame (n=76) and non-lame (n=25) horses acquired during ridden schooling-type work at both trot and canter. These included images of seven lame horses acquired before (n=30 photographs) and after diagnostic analgesia had abolished lameness (n=22 photographs).
A pain score (0-3; 0=normal, 1-3=abnormal) was applied to each feature in the ethogram, based on published descriptions of pain in horses.
A total of 27,407 facial markers were recorded, with those giving the greatest significant difference between lame and sound horses including ears back, eyes partially or fully closed, an open mouth with exposed teeth and being severely above the bit.
Pain scores were higher for lame horses than non-lame horses (p<0.001). Total pain score (p<0.05), total head position score (p<0.01), and total ear score (p<0.01) were reduced in lame horses after abolition of lameness.
Severely ‘above the bit’, twisting the head, asymmetrical position of the bit, ear position (both ears backwards, one ear backwards and one to the side, one ear backwards and one ear forwards) and eye features (exposure of the sclera, the eye partially or completely closed, muscle tension caudal to the eye, an intense stare) were the best indicators of pain.
The researchers concluded that application of the ethogram and pain score could differentiate between lame and non-lame horses. Assessment of facial expression could potentially improve recognition of pain-related gait abnormalities in ridden horses (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(17)30019-9/fulltext)
Sue and her team are now working on the development of a whole horse ethogram and its application to non-lame and lame horses, to help to differentiate between manifestations of conflict behaviour, in response to the demands of the rider, and pain. They are also working towards the development of a practical tool for recognising facial expressions, similar to that of a body condition score chart, which they say could dramatically improve the health and welfare of all horses.
Photo: Signs of pain include ears back (pain score of 3), intense stare, muscle tension and mouth. Courtesy Dr Sue Tyson.
A debate held at BEVA Congress last month ended with more than 70% of voters disagreeing with the motion: this house believes that new vet schools will benefit equine veterinary practice in the UK.
The result reflects a recent industry survey indicating that up to five times as many veterinary graduates may be seeking work in equine practice as there are jobs available.
Chris Proudman, founding head of Surrey University's new School of Veterinary Medicine and Mark Bowen, Associate Professor of Veterinary Internal Medicine at the University of Nottingham's School of Veterinary Medicine and Science, advocated that new UK vet schools are important for the advancement of the profession.
Mark Bowen said: "New UK vet schools will benefit the profession by improving the standards of veterinary education and creating what the consumer wants." He argued that new schools would help improve teaching methods and clinical training, while the resultant smaller class sizes would provide greater opportunities for hands on training. Competition would also help to drive up standards and inspire other universities to instigate much-needed changes such as focusing on quality of teaching rather than research.
Chris Proudman emphasised the flexibility of a new vet school to be progressive and innovative in both curriculum design and teaching delivery. He said: "Designing a curriculum from scratch allows novel approaches to partnership working and to the One Health agenda. New schools can deliver veterinary graduates better equipped with the skills and knowledge to be the veterinary leaders of the future."
The proposers also reasoned that if school leavers cannot find a place in a UK vet school they can now attend English language veterinary schools in universities across the EU, many of which do not have European accreditation to ensure standards of education. Therefore the increase in numbers of veterinary graduates is irresistible and the authorities can only influence the numbers trained in the UK and govern the high quality of teaching that is provided in the UK.
Alastair Welch, a partner at Donnington Grove Veterinary Group in Berkshire and Lucy Grieve, vet at Darley Pre-Training in Newmarket, staunchly countered the motion. They maintained that new vet schools would have a detrimental impact on the industry over the longer term and that their introduction demonstrated a slackening of the RCVS's management of the profession.
Alastair said: "Both anecdotal and empirical data suggest that becoming a horse vet has never been harder. The seemingly endless supply of hard-working, well-qualified school leavers determined to become equine vets provides universities with a reliable income stream for years to come but at what cost? I remain to be convinced that we will not end up educating veterinary graduates who cannot find a position in their intended career."
Lucy contended that it was irresponsible and immoral to allow individuals to commit five or six years, and tens of thousands of pounds, towards a veterinary career without them first being made aware of the limited opportunities available in very popular sectors of the profession such as equine practice.
Paul Jepson, President of BEVA, said: "With more than 70% of voters opposing the motion there is clearly a discernable level of disquiet amongst BEVA members about the current job market in equine practice and the further dilution of opportunities that increased numbers of graduates will create."
To help address the growing challenges faced by new graduates BEVA has recently introduced an Internship Awareness Programme (IAP). The scheme aims to help students and vets navigate the opportunities available as an intern and helps equine veterinary practices to find the most suitable employees for their practice.
You should be able to view the debate here: http://www.fsmevents.com/beva/congress13-session34. If not, the debate can be viewed on the BEVA website by following these instructions. Click the Webinar tab. Then click register. Then complete the £0 transaction and you will be able to access the free webinars. Select 'Free sessions' (Click the + symbol). Select 'Current Affairs: New vet schools - supply and demand?'
The company says the aim is to identify the most effective ways to minimise the risks this common and debilitating infectious equine virus poses. The survey can be found here.
Equine Herpes Virus is a contagious virus, which can cause respiratory disease, abortion and more rarely neurological disease. In addition, sub-clinical infections can be associated with a syndrome of poor performance and have a potential effect on the health of the whole yard.1
The disease is transmitted from horse to horse through the respiratory tract, by inhalation of the viral particles shed by infected horses. Once a horse is infected with Equine Herpes Virus it is likely to be latently infected for life. Viral reactivation and nasal shedding can occur at any time, particularly during stressful periods such as when mixing with other horses at equine events. This can lead to acute disease episodes. Often affected horses are asymptomatic but if they do show symptoms these may include depression, lethargy, pyrexia, nasal discharge and a dry cough. Reduction of shedding through management and vaccination is key to disease control.2
Wendy Talbot, National Equine Veterinary Manager at Zoetis said: "EHV has potentially serious health, performance and financial implications across every sector of the equestrian industry.
"The aim of our survey is to find out more about current vet protocols in practice. The results should help us to identify and then ensure that the most effective prevention strategies are accessible to vets and their clients."
The survey runs from 4 – 22nd March 2019 in parallel to a separate survey for horse owners.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
The RCVS Disciplinary Committee has reprimanded Gloucestershire veterinary surgeon Adele Lewis for failing to pass on information about a horse’s clinical history to a potential buyer during a pre-purchase examination.
Ms Lewis, the sole principal of the Cotswold Equine Clinic in Lechlade, Gloucestershire, carried out the examination of a pony called Luke on 13 February 2014. Luke was owned by Mrs Booth who was a long-established client of Ms Lewis, both at her previous practice, Bourton Vale, and at her current practice. The examination was carried out on behalf of the prospective purchaser, Mrs Grieve.
Upon examination Ms Lewis certified that, in her opinion, Luke’s veterinary history did not increase the risk of purchase.
Following the purchase of Luke, Mrs Grieve attempted to obtain insurance for Luke and found out from a pet insurance company that a claim had been made by Mrs Booth in September 2013. She subsequently found out that, following concerns expressed by Mrs Booth and her trainer about Luke’s movement and their wanting an expert opinion, Ms Lewis had referred him to Dr Kold, a Specialist in Equine Orthopaedics, in September 2013. Dr Kold had diagnosed Luke with lameness and had given him intra-articular medication. Luke had also had a follow-up appointment with Dr Kold about four weeks later in October 2013.
The Disciplinary Committee hearing commenced on Tuesday 13 October 2015. At the outset, Ms Lewis admitted several parts of the charges (charge A and charge B) against her. In regards to charge A, she admitted that she had failed to inform Mrs Grieve that, when she examined Luke on 24 September 2013, his then owner Mrs Booth had complained firstly that Luke was “not tracking up and going forward” and, secondly, that he had improved significantly when put on a Phenylbutazone trial. She also admitted that she had referred him to Dr Kold for a poor performance investigation and that she ought to have informed Mrs Grieve of these matters.
In regards to charge B, she admitted that she completed a Certificate of Veterinary Examination in which she had declared that Luke’s veterinary history did not increase the risk of purchase and allowed the vendor’s declaration to include assertions that there had been no previous lameness and no intra-articular medication given in the last 12 months. Ms Lewis admitted that she ought to have known that her declaration that Luke’s veterinary history did not increase the risk of purchase was incorrect.
However, Ms Lewis denied being aware that Dr Kold had diagnosed lameness, administered an intra-articular corticosteroid to Luke and examined and noted a problem with his breathing, including upper airway disease and possible lower airway disease. Furthermore, she denied dishonesty in regards to both the charges against her and in relation to vendor declarations made on the Certificate of Veterinary Examination regarding previous lameness and intra-articular medication.
During the course of the hearing, Ms Lewis told the Committee that she had not received the reports about the two consultations by Dr Kold (despite their having been sent to her by letter and, with respect to the second report, also by email) and that she was therefore unaware of his findings when she carried out the pre-purchase examination. She also stated that she had not been informed of these by Mrs Booth. During her evidence, Ms Lewis also admitted having entered inaccurate information on a veterinary report to assist with an insurance claim.
The Committee did not find Ms Lewis to be an impressive witness citing the fact that her “explanations as to her practice showed a worrying absence of probity in the completion of veterinary reports for the purposes of insurance claims, and an absence of any effective practice management, consistent with acceptable practice.”
However, the Committee felt it did not have the evidence to conclude that Ms Lewis had acted dishonestly during the pre-purchase examination. It cited the fact that her actions, when informed by the purchaser Mrs Grieve of Dr Kold’s examination, did not appear to be those of someone trying to cover their tracks.
In regards to charge A, the Committee also found that the “apparently chaotic manner in which Ms Lewis ran her practice, and her own opinion that the pony was sound, would appear to have led her to wrongly disregard these matters from disclosure.”
In making its decision on her conduct and sanction, the Committee said that Ms Lewis’ failure to fully communicate to Mrs Grieve all the relevant information about Luke’s veterinary history fell far short of the conduct expected from a veterinary surgeon. It also cited the utmost importance of a complete and accurate certification process, as made clear in the RCVS Code of Professional Conduct and the Twelve Principles of Certification.
Chitra Karve, chairing the Committee and speaking on its behalf, said: “The Committee continues to emphasise the importance of maintaining the integrity of veterinary certification in any aspect of practice. Mrs Grieve told this Committee that if she had been fully informed about Luke’s veterinary history she would not have purchased the pony. It is clear from the evidence that it affected Mrs Grieve’s ability to insure the pony. Ms Lewis has accepted that the information about Luke’s veterinary history, not having been disclosed, was capable of affecting the risk of purchase. The public are entitled to rely upon veterinary surgeons providing complete and accurate information, when certificates and reports are prepared.”
In mitigation, the Committee paid regard to Ms Lewis’ inexperience at running her own practice and found no issue with her competence or clinical ability as a veterinary surgeon. It concluded that she had acted out of character and that there was no financial motivation for her actions. It also found it “highly relevant that the facts admitted and found proved related to a single pre-purchase examination.”
It also noted that Ms Lewis has now put in place a practice management system and has shown insight into her actions, by taking active steps to better comply with her obligations under the Code of Professional Conduct. She had also made early admissions of guilt and made a full apology to both Mrs Grieve and the RCVS both at the outset of the hearing, and in her evidence.
Chitra Karve added: “Having had the opportunity of observing her demeanour at this hearing, the Committee believes that it is unlikely that she will repeat her conduct.... The Committee has concluded that an appropriate and proportionate response in this case is to reprimand Ms Lewis.”
Genitrix has launched a new system called Osteokine, which produces Platelet-Rich-Plasma (PRP). PRP, an autologous solution containing therapeutically significant concentrations of platelets, is known to accelerate the healing of injuries and is already widely used in human medicine. It is increasingly being used in the treatment of horses.
The Osteokine system, developed by German company Orthogen which also manufactures joint therapy Irap, comprises two interconnected blood bags.
The system involves taking citrated whole blood from the horse and placing it into the first, red-capped Osteokine bag for processing in a centrifuge. The plasma and platelets are then transferred to the second bag, and a second centrifuge process separates the plasma and generates a pellet of PRP, which is extracted and used to treat the horse from which it was taken.
Treatment with PRP has been shown to accelerate wound healing in all kinds of tissue particularly tendons and ligaments and has also been used in bone healing. It has been noted to reduce perioperative traumatic pain while the higher collagen content provided by PRP can create improved scar resistance.
Commenting on the launch of the Osteokine system in the UK, Rob Watkins, Marketing Director of Genitrix, said: "Therapeutic care of equine lameness is an area of particular expertise for Genitrix and the innovative treatments we've brought to market, including Acell, HY50 and Irap already form part of the staple ‘toolkit' of many equine vets.
"The benefits of PRP in terms of accelerating wound healing and vasculerisation are already widely accepted as are the advantages of an autologous approach in terms of eliminating the risk of disease transmission. To date, however, the process of extracting PRP has proved complex and expensive and only provided in specialised laboratories.
"Osteokine, in contrast, offers a cost-effective approach based on a system which is simple to operate in practice and takes only 20 minutes. We believe it offers a highly effective approach to treating wounds and injuries in horses."
For further information on Osteokine, contact Genitrix on 01403 786345.
Despite being a common disease, CVS says very little research has been undertaken into EPD in the UK.
In addition, numerous different treatments are currently used for EPD, for which there is not always robust scientific evidence.
The CVS study, which started in 2022 and will continue till early 2024, involves 20 practices.
Samples have been collected from over 70 cases from horses that have been diagnosed by EPD throughout the UK.
Full blood profiles have been assessed, in addition to bacterial culture analysis of the lesions, PCR analysis for dermatophytes (ringworm fungi), microscopy for ectoparasites (mites) and skin cytology.
An owner questionnaire has also been completed to gather information on EDP management.
Each horse’s lesions have been graded and descriptive data relating to the lesions were recorded.
Data collection is now complete and a team of researchers, led by vet Manuela Diaz Ramos, has started analysing the data.
A full report on the findings, along with treatment and management recommendations, is expected to be presented at a scientific conference later this year.
Dr Thomason initially denied both heads of charge, but on the third day of the hearing he changed his plea and admitted the charge in its entirety.
The first part of the charge related to the fact that the seller of the horse was a both a client of Dr Thomason’s practice and a personal friend of his, and he therefore had a potential and/or actual conflict of interest.
Dr Thomason did not disclose this professional and personal relationship to the prospective purchaser before the pre-purchase exam.
The prospective purchaser only discovered Dr Thomason’s relationship with the seller when reading the vetting certificate at home, and stated that, in the past, she had had a similar experience in which the horse was then found to be lame. She later found out the extent of the personal relationship, when invited to join the seller on a social media site.
The Committee found that, in this set of circumstances, Dr Thomason should not have undertaken the pre-purchase exam at all, and, at the very least, disclosed his personal and professional relationship with the vendor.
The Committee also found that although Dr Thomason did have a system in place to inform any prospective purchasers if the vendor was a client of his practice, this failed to work on this occasion and neither the practice nor Dr Thomason told the prospective buyer that the seller was a client before booking the pre-purchase exam. Dr Thomason had no similar system in place to disclose any close friendships with sellers.
Dr Thomason did not consider there was a conflict of interest as he felt confident he could carry out the pre-purchase exam impartially. In addition, it was his belief that the seller had been alerted to the conflict through a system in place at his practice, implemented to safeguard against this type of error. He stated that he in no way attempted to hide his relationship with the seller to the prospective purchaser.
It was not alleged that Dr Thomason had acted dishonestly.
Ultimately, the Committee found Dr Thomason not guilty of disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "Whilst the Committee concluded that the respondent’s view of his obligations to disclose both the professional and personal relationships he had with the vendor was mistaken, it did not find any improper motivation on his part. It has already noted that he sought to disclose to the prospective purchaser through his system the fact that the vendor was a professional client of his.
"The Committee has weighed all these matters very carefully. It is for the client to determine whether or not to proceed with a PPE when in possession of all relevant facts in relation to any potential conflict of interest, and not for the veterinary surgeon to decide. The autonomy of the client must be respected. The Committee was firmly of the opinion that a failure to comply with the Code is very serious. However, taking into account the particulars of this case, the Committee does not consider that the actions of the respondent amount to disgraceful conduct in a professional respect."
BEVA says it was aware, from both younger members and their employers, that there were some equine fields, for which the association had no courses, where newer graduates were lacking in clinical skills.
The new Equine Practice Fundamentals Programme comprises 10 individual CPD courses with a mix of lectures and hands-on practicals. BEVA says it builds on the broad training delivered by the universities to specifically provide the pragmatic knowledge and hands-on clinical skills needed by those in the early stages of an equine veterinary career.
The content was designed on the back of consultation with over 60 senior practitioners from across BEVA’s membership.
The average senior practitioner rated the likelihood that they would encourage recent graduates to attend the programme as 9/10 and BEVA says feedback on the initial course proposal was highly encouraging.
The courses cover:
David Mountford, Chief Executive of BEVA, said: "Because BEVA doesn’t seek to make a profit on its CPD we can deliver an outstanding programme that is both highly regarded and affordable. We anticipate that the series will become essential CPD for those looking to establish themselves in equine practice, for practices looking to support the development of new staff, and for employers looking to differentiate between candidates."
The first five courses will be running during 2018 and again in 2019 together with the remaining five. The full series of ten courses can be booked at a discounted rate. Alternatively, each course can be booked individually.
For further information visit https://www.beva.org.uk/Home/Education/CPD/The-Fundamentals-of-Equine-Practice
MSD Animal Health has announced the launch of KBHH Yard Master – a new preventative healthcare and biosecurity app - as part of its ongoing Keeping Britain’s Horses Healthy (KBHH) campaign.
MSD says KBHH Yard Master has been created to link vets and yards where the majority of horses in Britain are kept. It aims to play a key role in protecting the health and welfare of the herd and in safeguarding the yard’s reputation and business.
Peter Young, Equine Business Manager at MSD Animal Health said: "Good biosecurity is essential in building and maintaining the reputation of a yard which, in turn, impacts on owner satisfaction and retention. It remains, however, a poorly understood subject despite its importance. We’ve therefore invested in the creation of KBHH Yard Master to help vets, yard managers, their employees and horse owners focus on preventative health and biosecurity measures; making best practice seem more achievable and easier to implement.
He added: "We were also fortunate to have input from Professor Josh Slater, who has been heavily involved in developing the content, evaluation and grading system behind the app assessment."
KBHH Yard Master covers all aspects of biosecurity, including everyday husbandry practices, managing new arrivals, running isolation facilities, infection control and personnel movement. MSD says it will frame a dialogue with yard managers regarding preventative healthcare and biosecurity in situ and provide instant feedback on current practices and risk. Following the on-site assessment, a report can be sent to the yard manager with tailor-made recommendations and timings, detailing how they can improve their yard’s biosecurity performance.
Peter added: "Based on the data gathered through the KBHH campaign we know that approximately half of horses are vaccinated for ‘flu. This means that there will be horses on yards, visited by vets, that are not vaccinated. KBHH Yard Master will help identify those horses and allow the vet to recommend appropriate vaccination schedules."
MSD has produced a range of supporting KBHH Yard Master materials to promote understanding, participation and compliance amongst yard staff and owners, including posters and downloadable booklets which explain aspects such as disease prevention, infection control and outbreak control.
A certificate of excellence is also available to be awarded to those yards which, following assessment, have a low overall biosecurity risk.
For more information, contact your MSD Animal Health Equine Account Manager or call MSD on 01908 685685.
The kit uses an indirect semi-quantitative IgG antibody assay which provides an easy-to-read colour change which clearly distinguishes normal IgG levels (>8mg/ml; colourless), partial FPT (4-8mg/ml; pink) and levels generally considered diagnostic of complete FPT (<4mg/ml; purple).
Vetlabs says the kit has a proven sensitivity and specificity of 97.4% and 93.6% respectively, and responds equally well with anticoagulant whole blood, serum or plasma. And with no additional equipment or refrigerated storage required, it is a true field test.
Mike Fleming, CEO of Vetlab Supplies Ltd said: "It’s not often you get to launch an equine diagnostic that’s genuinely life saving. With Fastest IgG Equine, vets can now give a clear-cut Failure of Passive Transfer (FPT) diagnosis at farms, stables or equestrian centres – and all in just 10 minutes."
According to the company, as many as 1 in 5 new-born foals can suffer some degree of IgG FPT. Foals with no antibody protection, due to complete FTP, have an estimated 75% chance of contracting debilitating or life-threatening infection. Even foals with some protection following partial FPT have only a 50% chance of resisting invaders such as Anaplasma, Giardia and Cryptosporidium.
The new-born foal’s absorption of maternal antibodies is most efficient in the first 6 to 8 hours of life, effectively ceasing after 24 to 36 hours. Veterinary surgeons and managers of equestrian facilities have only this narrow window to recognise FPT and act to save a valuable new-born from life threatening infection.
Mike added: "With Fastest Equine as part of their field kit, equine vets are equipped to diagnose and treat antibody deficient foals with life-saving colostrum, colsotrum formula substitute, or administer oral or intravenous IgG, within that critical first 24 hours."
Mark Bowen, Associate Professor at The University of Nottingham, has been appointed as President of the British Equine Veterinary Association (BEVA) for 2015/16.
Mark will take over the role from Andrew Harrison at the end of BEVA Congress on 12th September. Vicki Nicholls, Veterinary Assistant at Wright and Morten Vets, Cheshire becomes President Elect.
He said: "BEVA’s strengths lie in its members, who are committed to the welfare of the horse and the advancement of clinical practice. With new benefits for members, a new website, a new role for the BEVA Trust and the highest quality of education, BEVA is now an even more forceful and effective voice for the equine profession, both internally and externally.
"Whilst the profession attempts to shape its future for the next 15 years, we must continue to support the innovative individuals in the profession who look ‘outside the box’ and make sure that the future of our profession, the next generation of veterinary surgeons, does not become restricted by dogma and tradition; that they too can replicate the level of innovation seen in equine practice over the last 50 years.
"It is vital that we continue to strengthen our relationships with the British Horseracing Authority and contribute to the development of a funding body to replace the Horserace Betting Levy Board. Our relationship with the BVA, the regulation of allied professionals, the rescheduling of ketamine, the new EU animal health regulations and EU medicines regulations, even the role of Europe, are key areas where BEVA will make veterinary voices heard for the benefit of equine welfare.
"Lastly, employment and retention of veterinary graduates in the profession is a cause of concern to us all. Over the next year we will enhance the Internship Awareness Programme and provide support and mentoring for the younger members of the profession. BEVA council is full of individuals committed to working on your behalf and I am looking forward to working alongside them all for the benefit of us all."
The term ‘evidence synthesis’ describes a range of methodological approaches used to systematically review, appraise, and summarise evidence on a specific area.
The approaches differ from conventional literature reviews or narrative reviews, which are not required to have a specified search strategy or methodology for appraising evidence, and usually present a personal perspective or opinion.
There are three main types of evidence syntheses: rapid reviews, systematic reviews, and scoping reviews.
All have key principles in common, which includes the formulation of a structured question, a systematic search of the available literature, a defined process of reviewing and selecting suitable publications, and a methodology for analysing the final included evidence.
Evidence synthesis is still not widely used in the equine veterinary world, despite its recognised value in human evidence-based medicine.
In the new virtual collection, the EVJ discusses the what and the why of this important evaluation method, as well as providing free access to all the equine veterinary evidence reviews published to date, including:
“Evidence synthesis makes an important contribution towards generating the evidence base which underpins equine clinical practice,” said Professor Sarah Freeman. “The challenge compared to human medicine is that equine veterinary data sets are much smaller, and study approaches and methodologies often vary significantly which means that it may not be possible to combine or collate data sets.
“Given this shortfall, scoping reviews can be helpful to identify what information is out there, find areas where a systematic review could be performed, and provide a useful summary for all the studies in a particular area.”
Professor Celia Marr, Editor of the EVJ said: “As increasing numbers of evidence syntheses are published, they will expand our understanding of the current bodies of evidence in veterinary medicine.
“The existing studies are already informing us on how we use evidence in our practices and policies, and it is encouraging to anticipate how they will shape our development of future research, to generate the best evidence as the norm, in every case.”
The virtual issue can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.evidence-synthesis-collection
Thousands of shipments of equine germinal product (semen, ova or embryos) are imported into the UK every year. It is a legal requirement for all imported equine semen to be accompanied to the place of destination (usually to the side of the mare) by an original, valid health certificate (ITAHC), issued in the country of origin.
The BEVA says that recently, consignments of equine semen have been imported without the appropriate health certificates meaning that there is no guarantee that the semen is free from the stated diseases or even that it is from the chosen stallion.
According to the Association, some well-known importing agents have been advising mare owners that these certificates are unnecessary and openly criticising veterinary surgeons who refuse to inseminate mares with uncertified imported semen.
The use of uncertified semen risks recipient mares being infected with diseases such as CEM or EVA, the potentially rapid spread of disease in breeding stock and eventual restrictions being placed on breeding premises. Recent outbreaks of Equine Infectious Anaemia (EIA) in Europe have increased the threat to the UK herd.
The personal and professional reputation of any veterinary surgeon involved with using uncertified semen is also in danger, with the RCVS likely to take a stringent line with any vets who disregard animal health laws and the high health status of British horses.
Malcolm Morley, Partner at Stable Close Equine Practice was recently placed in a difficult position with a longstanding client when semen arrived without the requisite documentation. Following a discussion between the semen importer and his client, where the client was told that Malcolm was being pedantic and that the client should find someone else to inseminate the mare, Malcolm contacted the importer saying: "We have no intention of inseminating the mare without the correct health papers. Please will you ensure that when you speak to the mare’s owner that you make it clear that you do not expect us to inseminate the mare in these circumstances and that the health papers should have been shipped with the semen."
Another BEVA member who wishes to remain anonymous said: "I have one very big client I think I may be about to lose because of my refusal to inseminate his mare without papers … (the importing stud) did not feel it worth a three hour drive to get papers done. The semen importer has made it clear to my client that (they believe) I am just being awkward."
Mark Bowen Senior Vice president of BEVA said: "Import agencies have placed additional pressure on the vets to inseminate mares without the necessary paperwork. Not only is this action illegal but places recipient mares under a direct threat from a notifiable and incurable disease. This seems particularly cavalier given the recent outbreaks of EIA across Europe."
Tullis Matson, Founder and Managing Director of Stallion AI Services said: "No one should be inseminating mares with imported semen that isn’t accompanied by the original health certificate. If the UK wants to retain its high health status and continue to utilise the international market it needs the breeding industry and the veterinary profession to use the disease controls that are currently place until such a time as we can implement more efficient system."
The BEVA says it is taking the following action:
Zoetis has announced the launch of Ketavet.
The intravenous anaesthetic solution containing ketamine is available in 10ml and 50ml presentations. The new product coincides with the re-classification of ketamine as a schedule 2 drug.
Ketavet is a clear, colourless solution for injection containing ketamine 100 mg/ml (equivalent to 115.36 mg/ml ketamine hydrochloride) with benzethonium chloride 0.1 mg/ml as a preservative. It can be used to induce anaesthesia in horses in conjunction with xylazine, detomidine or romifidine.
Ketavet, along with other ketamine containing products, has been moved to Schedule 2 of the Misuse of Drugs Regulations, which took effect from 30 November 2015. This enables tighter controls on the record keeping, prescribing and safe custody of products containing this active. More information on the specific requirements which will need to be met following the schedule change can be found on the VMD website https://www.gov.uk/government/news/amendments-to-the-misuse-of-drugs-regulations-2001
Penny McCann, Equine Product Manager at Zoetis said: "Ketavet is an important product in our anaesthesia portfolio. We are keen to help veterinary surgeons keep up-to-date with the reclassification of ketamine and with this in mind our new product packaging clearly reflects ketamine’s revised status as a schedule 2 drug."
For more information, contact your Zoetis Account Manager.
Merial has announced the results of a survey which suggests that whilst diagnosis of gastric ulcers in horses is improving, there is still room for improvement.
The survey of 50 equine vets, which was conducted in May this year, showed that the number of practices owning a scope has more than doubled over the past six years. Half of equine practices now own a scope. Over the same period the average number of monthly scopes has risen from 1.5 to 9.25 and referrals from practices without a scope has risen by 65%.
Merial's Louise Radford MRCVS said: "The survey also showed that symptom recognition among vets prompting the need for an endoscopy has also risen. The vast majority of vets now consider changes in behaviour, loss of appetite and poor performance as potential signs. In addition, 100% of those surveyed would consider an endoscopy when presented with the signs of recurring colic.
"However whilst this is great progress, when diagnosis is compared to the incidence of ulcer, we know that more needs to be done. It is believed that up to 30% of leisure horses have some degree of gastric ulceration, and this increases in sports horses, yet just a fraction of this figure represents those scoped."
Richard Hepburn BVSc MS(Hons) CertEM(IntMed) DipACVIM(LA) MRCVS, American and RCVS Specialist in Equine Internal Medicine at B&W Equine Hospital says he is pleased that more horses are being scoped for gastric ulcers but says that further education is needed: "We've seen a huge leap in the appreciation of the incidence of gastric ulceration in non-racing animals, which long term will better our understanding of the individual clinical relevance of particular lesions, and the benefits of treatment and management change.
"This should improve both performance and horse welfare, as well as increasing client satisfaction. Despite the huge increase in the diagnosis and treatment of equine gastric ulcers it is still believed that many horses go undiagnosed."
EQVALAN® manufacturer Merial Animal Health is extending its free egg worm count promotion, allowing practices to re-run the offer this autumn.
During September and October Merial is giving away 20 free faecal egg count tests with each order of 20 tubes of EQVALAN® DUO (ivermectin + praziquantel). In addition, for every 20 tubes ordered, stockists will get a further 4 tubes of EQVALAN® DUO free.
EQVALAN's product manager Claire Edmunds said: "During the spring campaign, over 1000 horse owners took part in the worm egg count promotion, many of whom we believe had never used testing kits before.
"The tests highlight which horses need treatment and which do not, allowing practices to advise specifically on the necessary treatment*.
For those practices with their own testing facilities, Merial is also offering promotional support to help encourage increased uptake and client buy-in. "The autumn campaign will provide participating practices with another opportunity to add value whilst encouraging loyalty from clients.
Claire added: "Promoting a targeted approach to responsible worming means that only those horses which need treatment are wormed with an appropriate wormer selected for the worms identified from the test."
For further information please contact your local territory manager or call the Merial Customer Support Centre on 0845 601 4236.